AIM ImmunoTech (AIM ImmunoTech) Debt-to-Equity : 0.07 (As of Dec. 2023)

View and export this data going back to 1995. Start your Free Trial

What is AIM ImmunoTech Debt-to-Equity?

AIM ImmunoTech's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.22 Mil. AIM ImmunoTech's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.50 Mil. AIM ImmunoTech's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $10.23 Mil. AIM ImmunoTech's debt to equity for the quarter that ended in Dec. 2023 was 0.07.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for AIM ImmunoTech's Debt-to-Equity or its related term are showing as below:

AIM' s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.05 Max: 1.15
Current: 0.07

During the past 13 years, the highest Debt-to-Equity Ratio of AIM ImmunoTech was 1.15. The lowest was 0.00. And the median was 0.05.

AIM's Debt-to-Equity is ranked better than
66.42% of 1072 companies
in the Biotechnology industry
Industry Median: 0.145 vs AIM: 0.07

AIM ImmunoTech Debt-to-Equity Historical Data

The historical data trend for AIM ImmunoTech's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AIM ImmunoTech Debt-to-Equity Chart

AIM ImmunoTech Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.48

0.04

0.02

0.07

AIM ImmunoTech Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															0.02	0.02	0.03	0.03	0.07

Competitive Comparison of AIM ImmunoTech's Debt-to-Equity

For the Biotechnology subindustry, AIM ImmunoTech's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AIM ImmunoTech's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AIM ImmunoTech's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where AIM ImmunoTech's Debt-to-Equity falls into.

AIM ImmunoTech Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

AIM ImmunoTech's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.223	+	0.495)	/	10.234
	=	0.07

AIM ImmunoTech's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.223	+	0.495)	/	10.234
	=	0.07

AIM ImmunoTech (AMEX:AIM) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

AIM ImmunoTech Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of AIM ImmunoTech's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

AIM ImmunoTech (AIM ImmunoTech) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AIM ImmunoTech Inc (AMEX:AIM) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

HXB2:Germany

Address

2117 SW Highway 484, Ocala, FL, USA, 34473

Website

https://www.aimimmuno.com

AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders, viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases and drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer and triple negative metastatic breast cancer. The company is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.

Executives

Thomas K. Equels	director, officer: Vice Chairman of Board	2117 SOUTHWEST HIGHWAY 484, OCALA FL 34473
Nancy Bryan	director	550 HILLS DRIVE, 3RD FLOOR, BEDMINSTER NJ 07921
Stewart Appelrouth	director	2117 SW HIGHWAY 484, OCALA FL 34473
Rodino Peter W. Iii	director	2117 SOUTHWEST HIGHWAY 484, OCALA FL 34473
Ellen M Lintal	officer: CFO	2117 SW HWY 484, OCALA FL 34473
William M Mitchell	director	2117 SW HWY 484, OCALA FL 34473
Wayne S. Springate	officer: VP of Operations	600 MAIN STREET, SUITE 2, RIVERTON NJ 08077
David R Strayer	other: Medical Director	600 MAIN STREET, SUITE 2, RIVERTON NJ 08077
Adam Pascale	officer: CFO	600 MAIN STREET, SUITE 2, RIVERTON NJ 08077
Ralph Christopher Cavalli	officer: VP, Quality Control	510 MURDOCH ROAD, PHILADELPHIA PA 19119
Russel J Lander	officer: VP of Process/QualityAssurance	784 BAEDER ROAD, JENKINTOWN PA 19046
Robert Iv Dickey	officer: Senior Vice President	320 WEST MERMAID LANE, PHILADELPHIA PA 19118
Bernhardt Charles Thomas Iii	officer: CFO	23 BIRCH ROAD, MALVERN PA 19355
Steven D Spence	director	250 EAST 54TH STREET APARTMENT 36C, NEW YORK NY 10022
Anthony Bonelli	officer: President & COO	P.O. BOX 521, NEW VERNON NJ 07976